Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial.

Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons DL, Sperl-Hillen JA, Bigger T, Cuddihy R, O'Conner PJ, Sood A, Zhang P, Sullivan MD; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators.

Diabetes Care. 2011 Apr;34(4):807-12. doi: 10.2337/dc10-1926. Epub 2011 Feb 23.

2.

Glycaemia and correlates of patient-reported outcomes in ACCORD trial participants.

Ali MK, Feeney P, Hire D, Simmons DL, O'Connor PJ, Ganz-Lord F, Goff D Jr, Zhang P, Anderson RT, Narayan KM, Sullivan MD.

Diabet Med. 2012 Jul;29(7):e67-74. doi: 10.1111/j.1464-5491.2011.03532.x.

PMID:
22141437
3.

Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus.

Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C; VACSDM Study Group.

J Diabetes Complications. 2005 Jul-Aug;19(4):207-11.

PMID:
15993354
4.

Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial.

O'Connor PJ, Narayan KM, Anderson R, Feeney P, Fine L, Ali MK, Simmons DL, Hire DG, Sperl-Hillen JM, Katz LA, Margolis KL, Sullivan MD.

Diabetes Care. 2012 Jul;35(7):1479-81. doi: 10.2337/dc11-1868. Epub 2012 May 14.

5.

Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.

Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; ACCORD MIND investigators.

Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28.

6.

Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes.

Opsteen C, Qi Y, Zinman B, Retnakaran R.

J Eval Clin Pract. 2012 Apr;18(2):256-61. doi: 10.1111/j.1365-2753.2010.01552.x. Epub 2010 Sep 16.

PMID:
20846320
7.

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.

Kaukua JK, Pekkarinen TA, Rissanen AM.

Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.

PMID:
14770192
8.

Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.

Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; ACCORD Investigators.

Diabetes Care. 2014;37(3):634-43. doi: 10.2337/dc13-1545. Epub 2013 Oct 29.

9.

Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.

Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KM, Nwachuku C, O'Connor PJ, Zhang P; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):90i-102i. Epub 2007 Apr 13.

PMID:
17599429
10.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME.

BMJ. 2010 Jan 8;340:b4909. doi: 10.1136/bmj.b4909.

11.

Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.

Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, Hamdy O, Abrahamson M, Clancy K, Foster K, Lautz D, Vernon A, Goldfine AB.

JAMA Surg. 2014 Jul;149(7):716-26. doi: 10.1001/jamasurg.2014.514.

12.

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.

Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators.

Diabetes Care. 2010 May;33(5):983-90. doi: 10.2337/dc09-1278.

13.

Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy.

Sullivan MD, O'Connor P, Feeney P, Hire D, Simmons DL, Raisch DW, Fine LJ, Narayan KM, Ali MK, Katon WJ.

Diabetes Care. 2012 Aug;35(8):1708-15. doi: 10.2337/dc11-1791. Epub 2012 May 22.

14.

Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.

Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC.

J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31.

PMID:
22851487
15.

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.

Rom J Intern Med. 2003;41(2):153-62.

PMID:
15526500
16.

Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.

Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, Josse RG, Schnall AM, Simmons DL, Hue TF, Palermo L, Hamilton BP, Green JB, Atkinson HH, O'Connor PJ, Force RW, Bauer DC.

Diabetes Care. 2012 Jul;35(7):1525-31. doi: 10.2337/dc11-2184.

17.

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.

Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Paré G, Mannino GC, Buranasupkajorn P, Mendonca C, Hastings T, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2016 Nov;39(11):1915-1924. Epub 2016 Aug 15.

18.

Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.

Writing Team for the DCCT/EDIC Research Group, Gubitosi-Klug RA, Sun W, Cleary PA, Braffett BH, Aiello LP, Das A, Tamborlane W, Klein R.

JAMA Ophthalmol. 2016 Feb;134(2):137-45. doi: 10.1001/jamaophthalmol.2015.4606.

19.

Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD.

Hoogwerf BJ; Action to Control Cardiovascular Risk in; Diabetes Study Group.

Cleve Clin J Med. 2008 Oct;75(10):729-37. Review.

PMID:
18939389
20.

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.

Vinik AI, Zhang Q.

Diabetes Care. 2007 Apr;30(4):795-800. Epub 2007 Jan 26. Erratum in: Diabetes Care. 2007 Jun;30(6):1684.

PMID:
17259481

Supplemental Content

Support Center